webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Fmoc-Lys(IvDde)-OH

  CAS No.: 204777-78-6   Cat No.: BADC-01589   Purity: ≥ 98% 4.5  

Fmoc-Lys(IvDde)-OH is a lysine derivative with orthogonal protecting groups, enabling stepwise ADC linker synthesis. It supports multifunctional conjugation, facilitating controlled payload attachment and spacer design for improved antibody-drug conjugate stability and performance.

Fmoc-Lys(IvDde)-OH

Structure of 204777-78-6

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C34H42N2O6
Molecular Weight
574.72
Shipping
Store at 2-8°C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
Fmoc-L-Lys(ivDde)-OH; (S)-2-((((9H-Fluoren-9-Yl)Methoxy)Carbonyl)Amino)-6-((1-(4,4-Dimethyl-2,6-Dioxocyclohexylidene)-3-Methylbutyl)Amino)Hexanoic Acid; N-Fmoc-N'-[1-(4,4-Dimethyl-2,6-Dioxocyclohex-1-Ylidene)-3-Methylbutyl]-L-Lysine
IUPAC Name
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[[1-(2-hydroxy-4,4-dimethyl-6-oxocyclohexen-1-yl)-3-methylbutylidene]amino]hexanoic acid
Canonical SMILES
CC(C)CC(=NCCCCC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13)C4=C(CC(CC4=O)(C)C)O
InChI
InChI=1S/C34H42N2O6/c1-21(2)17-28(31-29(37)18-34(3,4)19-30(31)38)35-16-10-9-15-27(32(39)40)36-33(41)42-20-26-24-13-7-5-11-22(24)23-12-6-8-14-25(23)26/h5-8,11-14,21,26-27,37H,9-10,15-20H2,1-4H3,(H,36,41)(H,39,40)/t27-/m0/s1
InChIKey
LHJJUCZESVFWSO-MHZLTWQESA-N
Density
1.183±0.06 g/cm3(Predicted)
Appearance
White to off-white crystalline powder
Quantity
Data not available, please inquire.
Storage
Store at 2-8°C
Boiling Point
765.6±60.0 °C(Predicted)

Fmoc-Lys(IvDde)-OH is a protected amino acid derivative commonly used in peptide synthesis. It offers specific features that are highly beneficial for various applications in bioscience. Here are some key applications of Fmoc-Lys(IvDde)-OH:

Solid-Phase Peptide Synthesis (SPPS): Fmoc-Lys(IvDde)-OH is routinely utilized in SPPS due to its compatibility with Fmoc/tBu chemistry. Its selective deprotection of the ε-amino group allows for the synthesis of complex peptide sequences with minimal side reactions. This makes it invaluable for constructing peptides with specific post-translational modifications or for introducing bioconjugation sites.

Drug Development: In drug discovery, Fmoc-Lys(IvDde)-OH facilitates the synthesis of bioactive peptides and peptide-based therapeutics. The discrete protection offered by IvDde allows for selective functionalization at the lysine residue without affecting other amino acids. This precision is essential for the development of highly specific and effective peptide drugs.

Protein Engineering: Fmoc-Lys(IvDde)-OH is used in the field of protein engineering to introduce functional groups or labels at specific sites on a protein. The ability to selectively deprotect the ε-amino group enables site-specific modifications such as the attachment of fluorescent dyes or affinity tags. This application is crucial for studying protein interactions, dynamics, and localization.

Bioconjugation: Fmoc-Lys(IvDde)-OH is employed in the synthesis of conjugated biomolecules for diverse applications, including targeted drug delivery and diagnostic imaging. The protected lysine’s ε-amino group can be selectively exposed to link a variety of functional molecules, such as polymers, antibodies, or nanoparticles. This targeted conjugation enhances the specificity and efficacy of the resulting bioconjugates.

1. Alkynyl phosphonate DNA: a versatile "click"able backbone for DNA-based biological applications
Heera Krishna, Marvin H Caruthers J Am Chem Soc. 2012 Jul 18;134(28):11618-31. doi: 10.1021/ja3026714. Epub 2012 Jul 6.
Major hurdles associated with DNA-based biological applications include, among others, targeted cell delivery, undesirable nonspecific effects, toxicity associated with various analogues or the reagents used to deliver oligonucleotides to cells, and stability toward intracellular enzymes. Although a plethora of diverse analogues have been investigated, a versatile methodology that can systematically address these challenges has not been developed. In this contribution, we present a new, Clickable, and versatile chemistry that can be used to rapidly introduce diverse functionality for studying these various problems. As a demonstration of the approach, we synthesized the core analogue, which is useful for introducing additional functionality, the triazolylphosphonate, and present preliminary data on its biological properties. We have developed a new phosphoramidite synthon--the alkynyl phosphinoamidite, which is compatible with conventional solid-phase oligonucleotide synthesis. Postsynthesis, the alkynylphosphonate can be functionalized via "Click" chemistry to generate the 1,2,3-triazolyl or substituted 1,2,3-triazolyl phosphonate-2'-deoxyribonucleotide internucleotide linkage. This manuscript describes the automated, solid-phase synthesis of mixed backbone oligodeoxyribonucleotides (ODNs) having 1,2,3-triazolylphosphonate (TP) as well as phosphate or thiophosphate internucleotide linkages and also 2'-OMe ribonucleotides and locked nucleic acids (LNAs) at selected sites. Nuclease stability assays demonstrate that the TP linkage is highly resistant toward 5'- and 3'-exonucleases, whereas melting studies indicate a slight destabilization when a TP-modified ODN is hybridized to its complementary RNA. A fluorescently labeled 16-mer ODN modified with two TP linkages shows efficient cellular uptake during passive transfection. Of particular interest, the subcellular distribution of TP-modified ODNs is highly dependent on cell type; a significant nuclear uptake is observed in HeLa cells, whereas diffuse cytoplasmic fluorescence is found in the WM-239A cell line. Cytoplasmic distribution is also present in human neuroblastoma cells (SK-N-F1), but Jurkat cells show both diffuse and punctate cytoplasmic uptake. Our results demonstrate that triazolylphosphonate ODNs are versatile additions to the oligonucleotide chemist's toolbox relative to designing new biological research reagents.
2. Solid-phase synthesis, thermal denaturation studies, nuclease resistance, and cellular uptake of (oligodeoxyribonucleoside)methylborane phosphine-DNA chimeras
Heera Krishna, Marvin H Caruthers J Am Chem Soc. 2011 Jun 29;133(25):9844-54. doi: 10.1021/ja201314q. Epub 2011 Jun 7.
The major hurdle associated with utilizing oligodeoxyribonucleotides for therapeutic purposes is their poor delivery into cells coupled with high nuclease susceptibility. In an attempt to combine the nonionic nature and high nuclease stability of the P-C bond of methylphosphonates with the high membrane permeability, low toxicity, and improved gene silencing ability of borane phosphonates, we have focused our research on the relatively unexplored methylborane phosphine (Me-P-BH(3)) modification. This Article describes the automated solid-phase synthesis of mixed-backbone oligodeoxynucleotides (ODNs) consisting of methylborane phosphine and phosphate or thiophosphate linkages (16-mers). Nuclease stability assays show that methylborane phosphine ODNs are highly resistant to 5' and 3' exonucleases. When hybridized to a complementary strand, the ODN:RNA duplex was more stable than its corresponding ODN:DNA duplex. The binding affinity of ODN:RNA duplex increased at lower salt concentration and approached that of a native DNA:RNA duplex under conditions close to physiological saline, indicating that the Me-P-BH(3) linkage is positively charged. Cellular uptake measurements indicate that these ODNs are efficiently taken up by cells even when the strand is 13% modified. Treatment of HeLa cells and WM-239A cells with fluorescently labeled ODNs shows significant cytoplasmic fluorescence when viewed under a microscope. Our results suggest that methylborane phosphine ODNs may prove very valuable as potential candidates in antisense research and RNAi.
3. Synthesis of novel cationic spermine-conjugated phosphotriester oligonucleotide for improvement of cell membrane permeability
Junsuke Hayashi, Tomoko Hamada, Ikumi Sasaki, Osamu Nakagawa, Shun-ichi Wada, Hidehito Urata Bioorg Med Chem Lett. 2015 Sep 1;25(17):3610-5. doi: 10.1016/j.bmcl.2015.06.071. Epub 2015 Jun 27.
A spermine-conjugated ethyl phosphotriester oligonucleotide was obtained by solid-phase synthesis based on phosphoramidite chemistry. The ethyl phosphotriester linkage was robust to exonuclease digestion and stable in fetal bovine serum. Cell membrane permeability of the spermine-conjugated ethyl phosphotriester oligonucleotide was studied by fluorescence experiments. The effective cell penetrating potency of the spermine-conjugated ethyl phosphotriester oligonucleotide was determined by confocal laser scanning microscopy and measurement of intracellular fluorescence intensity.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Propargyl-PEG9-bromide
Send Inquiry
Verification code
Inquiry Basket